[1]
|
Whittaker, C., Walker, P., Alhaffar, M., et al. (2021) Under-Reporting of Deaths Limits Our Understanding of True Burden of COVID-19. BMJ, 375, Article No. n2239. https://doi.org/10.1136/bmj.n2239
|
[2]
|
Biswas, M., Raham-an, S., Biswas, T.K., et al. (2020) Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology, 1-12.
|
[3]
|
Mukherjee, A., Kumar, G., Turuk, A., et al. (2023) Vaccination Saves Lives: A Real-Time Study of Patients with Chronic Diseases and Severe COVID-19 Infection. QJM: An International Journal of Medicine, 116, 47-56.
https://doi.org/10.1093/qjmed/hcac202
|
[4]
|
Cichoż-Lach, H. and Michalak, A. (2021) Liver Injury in the Era of COVID-19. World Journal of Gastroenterology, 27, 377-390. https://doi.org/10.3748/wjg.v27.i5.377
|
[5]
|
Alqahtani, S.A., Aljumah, A.A., Hashim, A., et al. (2020) Principles of Care for Patients with Liver Disease during the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. Annals of Saudi Medicine, 40, 273-280. https://doi.org/10.5144/0256-4947.2020.273
|
[6]
|
Boettler, T., Marjot, T., Newsome, P.N., et al. (2020) Impact of COVID-19 on the Care of Patients with Liver Disease: EASL-ESCMID Position Paper after 6 Months of the Pandemic. JHEP Reports, 2, Article ID: 100169.
https://doi.org/10.1016/j.jhepr.2020.100169
|
[7]
|
Singh, S. and Khan, A. (2020) Clinical Characteristics and Out-comes of Coronavirus Disease 2019 among Patients with Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 159, 768-771. https://doi.org/10.1053/j.gastro.2020.04.064
|
[8]
|
Nagarajan, R., Krishnamoorthy, Y., Rajaa, S. and Hariharan, V.S. (2022) COVID-19 Severity and Mortality among Chronic Liver Disease Patients: A Systematic Review and Me-ta-Analysis. Preventing Chronic Disease, 19, E53.
https://doi.org/10.5888/pcd19.210228
|
[9]
|
Steele, M.K., Couture, A., Reed, C., et al. (2022) Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented among Vaccinated Persons in the US, December 2020 to September 2021. JAMA Network Open, 5, e2220385. https://doi.org/10.1001/jamanetworkopen.2022.20385
|
[10]
|
Tulimilli, S.V., Dallavalasa, S., Basavaraju, C.G., et al. (2022) Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vac-cines, 10, Article No. 1751.
https://doi.org/10.3390/vaccines10101751
|
[11]
|
Ioannou, G.N., Liang, P.S., Locke, E., et al. (2021) Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventila-tion, and Mortality. Hepatology, 74, 322-335.
https://doi.org/10.1002/hep.31649
|
[12]
|
Kim, D., Adeniji, N., Latt, N., et al. (2021) Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-Center Study. Clinical Gastroenterology and Hepatology, 19, 1469-1479.
https://doi.org/10.1016/j.cgh.2020.09.027
|
[13]
|
Moon, A.M., Webb, G.J., Aloman, C., et al. (2020) High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-Existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry. Journal of Hepatology, 73, 705-708. https://doi.org/10.1016/j.jhep.2020.05.013
|
[14]
|
Marjot, T., Moon, A.M., Cook, J.A., et al. (2021) Outcomes Fol-lowing SARS-CoV-2 Infection in Patients with Chronic Liver Disease: An International Registry Study. Journal of Hepatology, 74, 567-577.
https://doi.org/10.1016/j.jhep.2020.09.024
|
[15]
|
Sagnelli, C., Montella, L., Grimaldi, P., et al. (2022) COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens, 11, Article No. 816. https://doi.org/10.3390/pathogens11070816
|
[16]
|
Yu, Y., Li, X. and Wan, T. (2023) Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis. Digestive Diseases and Sciences, 68, 1615-1631. https://doi.org/10.1007/s10620-022-07687-2
|
[17]
|
Marjot, T., Buescher, G., Sebode, M., et al. (2021) SARS-CoV-2 Infection in Patients with Autoimmune Hepatitis. Journal of Hepatology, 74, 1335-1343. https://doi.org/10.1016/j.jhep.2021.01.021
|
[18]
|
Chavez-Tapia, N.C., Torre-Delgadillo, A., Tellez-Avila, F.I. and Uribe, M. (2007) The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis. Current Medicinal Chemistry, 14, 2954-2958.
https://doi.org/10.2174/092986707782794041
|
[19]
|
Sharma P., Kumar A., Anikhindi S., et al. (2021) Effect of COVID-19 on Pre-Existing Liver Disease: What Hepatologist Should Know? Journal of Clinical and Experimental Hepatology, 11, 484-493.
https://doi.org/10.1016/j.jceh.2020.12.006
|
[20]
|
Premkumar, M. and Kedarisetty, C.K. (2021) Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. Journal of Clinical and Translational Hepatology, 9, 256-264.
https://doi.org/10.14218/JCTH.2021.00055
|
[21]
|
Khandker, S.S., Godman, B., Jawad, M.I., et al. (2021) A Sys-tematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 9, Article No. 1387. https://doi.org/10.3390/vaccines9121387
|
[22]
|
Amodio, E., Minutolo, G., Casuccio, A., et al. (2022) Adverse Reac-tions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System. Vaccines, 10, Article No. 345.
https://doi.org/10.3390/vaccines10030345
|
[23]
|
Xia, S., Zhang, Y., Wang, Y., et al. (2021) Safety and Immuno-genicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial. The Lancet Infectious Diseases, 21, 39-51. https://doi.org/10.1016/S1473-3099(20)30831-8
|
[24]
|
Novak, N., Tordesillas, L. and Cabanillas, B. (2022) Adverse Rare Events to Vaccines for COVID-19: From Hypersensitivity Reactions to Thrombosis and Thrombocytopenia. Inter-national Reviews of Immunology, 41, 438-447.
https://doi.org/10.1080/08830185.2021.1939696
|
[25]
|
Chen, Y., Xu, Z., Wang, P., et al. (2022) New-Onset Auto-immune Phenomena Post-COVID-19 Vaccination. Immunology, 165, 386-401. https://doi.org/10.1111/imm.13443
|
[26]
|
Wong, C.K.H., Mak, L.Y., Au, I., et al. (2022) Risk of Acute Liver Injury Following the mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccines. Journal of Hepatology, 77, 1339-1348.
https://doi.org/10.1016/j.jhep.2022.06.032
|
[27]
|
Vojdani, A. and Kharrazian, D. (2020) Potential Antigenic Cross-Reactivity between SARS-CoV-2 and Human Tissue with a Possible Link to an Increase in Autoimmune Diseases. Clinical Immunology, 217, Article ID: 108480.
https://doi.org/10.1016/j.clim.2020.108480
|
[28]
|
Roy, A., Verma, N., Singh, S., et al. (2022) Immune-Mediated Liver Injury Following COVID-19 Vaccination: A Systematic Review. Hepatology Communications, 6, 2513-2522. https://doi.org/10.1002/hep4.1979
|
[29]
|
Cao, Z., Gui, H., Sheng, Z., Xin, H. and Xie, Q. (2022) Letter to the Editor: Exacerbation of Autoimmune Hepatitis after COVID-19 Vaccination. Hepatology, 75, 757-759. https://doi.org/10.1002/hep.32269
|
[30]
|
Luo, D., Chen, X., Du, J., et al. (2023) Immunogenicity of COVID-19 Vaccines in Chronic Liver Disease Patients and Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Liver International, 43, 34-48.
https://doi.org/10.1111/liv.15403
|
[31]
|
Thuluvath, P.J., Robarts, P. and Chauhan, M. (2021) Analysis of Antibody Responses after COVID-19 Vaccination in Liver Transplant Recipients and Those with Chronic Liver Diseases. Journal of Hepatology, 75, 1434-1439.
https://doi.org/10.1016/j.jhep.2021.08.008
|
[32]
|
Willuweit, K., Frey, A., Passenberg, M., et al. (2022) Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of An-tibody Titers. Vaccines, 10, Article No. 377.
https://doi.org/10.3390/vaccines10030377
|
[33]
|
Ruether, D.F., Schaub, G.M., Duengelhoef, P.M., et al. (2022) SARS-CoV2-Specific Humoral and T-Cell Immune Response after Second Vaccination in Liver Cirrhosis and Trans-plant Patients. Clinical Gastroenterology and Hepatology, 20, 162-172. https://doi.org/10.1016/j.cgh.2021.09.003
|
[34]
|
Doi, H., Iyer, T.K., Carpenter, E., et al. (2012) Dysfunctional B-Cell Activation in Cirrhosis Resulting from Hepatitis C Infection Associated with Disappearance of CD27-Positive B-Cell Population. Hepatology, 55, 709-719.
https://doi.org/10.1002/hep.24689
|
[35]
|
John, B.V., Sidney, B.A.T., Moon, A., et al. (2022) Effectiveness of COVID-19 Viral Vector Ad.26.COV2.S Vaccine and Comparison with mRNA Vaccines in Cirrhosis. Clinical Gastro-enterology and Hepatology, 20, 2405-2408.
https://doi.org/10.1016/j.cgh.2022.05.038
|
[36]
|
John, B.V., Deng, Y., Schwartz, K.B., et al. (2022) Postvaccination COVID-19 Infection Is Associated with Reduced Mortality in Patients with Cirrhosis. Hepatology, 76, 126-138. https://doi.org/10.1002/hep.32337
|
[37]
|
Cao, Z., Zhang, C., Zhao, S., et al. (2022) COVID-19 Vaccines in Patients with Decompensated Cirrhosis: A Retrospective Cohort on Safety Data and Risk Factors Associated with Unvaccinated Status. Infectious Diseases of Poverty, 11, Article No. 56. https://doi.org/10.1186/s40249-022-00982-0
|
[38]
|
Bakasis, A.-D., Bitzogli, K., Mouziouras, D., et al. (2022) Anti-body Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses, 14, Article No. 207. https://doi.org/10.3390/v14020207
|
[39]
|
Davidov, Y., Tsaraf, K., Cohen-Ezra, O., et al. (2022) Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine among Liver Transplantation Recipients. Liver Transplantation, 28, 215-223.
https://doi.org/10.1002/lt.26366
|
[40]
|
D’Offizi. G., Agrati. C., Visco-Comandini. U., et al. (2022) Coordinated Cellular and Humoral Immune Responses after Two-Dose SARS-CoV2 mRNA Vaccination in Liver Transplant Recipi-ents. Liver International, 42, 180-186.
https://doi.org/10.1111/liv.15089
|
[41]
|
Rabinowich, L., Grupper, A., Baruch, R., et al. (2021) Low Immunogenicity to SARS-CoV-2 Vaccination among Liver Transplant Recipients. Journal of Hepatology, 75, 435-438. https://doi.org/10.1016/j.jhep.2021.04.020
|
[42]
|
Sakai, A., Morishita, T. and Matsunami, H. (2022) Antibody Re-sponse after a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients. Transplant International, 35, Article ID: 10321.
https://doi.org/10.3389/ti.2022.10321
|
[43]
|
Timmermann, L., Globke, B., Lurje, G., et al. (2021) Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients. Vaccines, 9, Article No. 1422. https://doi.org/10.3390/vaccines9121422
|
[44]
|
Fix, O.K., Blumberg, E.A., Chang, K.M., et al. (2021) American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Dis-ease 2019 Infection in Patients with Liver Disease. Hepatology, 74, 1049-1064. https://doi.org/10.1002/hep.31751
|
[45]
|
Kamar, N., Abravanel, F., Marion, O., et al. (2021) Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 385, 661-662. https://doi.org/10.1056/NEJMc2108861
|
[46]
|
Oosting, S.F., van der Veldt, A., Fehrmann, R., et al. (2022) Immu-nogenicity after Second and Third mRNA-1273 Vaccination Doses in Patients Receiving Chemotherapy, Immunotherapy, or Both for Solid Tumours. The Lancet Oncology, 23, 833-835. https://doi.org/10.1016/S1470-2045(22)00203-0
|
[47]
|
Peeters, M., Verbruggen, L., Teuwen, L., et al. (2021) Re-duced Humoral Immune Response after BNT162b2 Coronavirus Disease 2019 Messenger RNA Vaccination in Cancer Patients under Antineoplastic Treatment. ESMO Open, 6, Article ID: 100274. https://doi.org/10.1016/j.esmoop.2021.100274
|
[48]
|
Levin, E.G., Lustig, Y., Cohen, C., et al. (2021) Waning Im-mune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 385, e84. https://doi.org/10.1056/NEJMoa2114583
|
[49]
|
He, T., Zhou, Y., Xu, P., et al. (2022) Safety and Antibody Re-sponse to Inactivated COVID-19 Vaccine in Patients with Chronic Hepatitis B Virus Infection. Liver International, 42, 1287-1296. https://doi.org/10.1111/liv.15173
|
[50]
|
Xiang, T., Liang, B., Wang, H., et al. (2021) Safety and Immu-nogenicity of a SARS-CoV-2 Inactivated Vaccine in Patients with Chronic Hepatitis B Virus Infection. Cellular & Mo-lecular Immunology, 18, 2679-2681.
https://doi.org/10.1038/s41423-021-00795-5
|
[51]
|
Wang, J., Hou, Z., Liu, J., et al. (2021) Safety and Immunogen-icity of COVID-19 Vaccination in Patients with Non-Alcoholic Fatty Liver Disease (CHESS2101): A Multicenter Study. Journal of Hepatology, 75, 439-441.
https://doi.org/10.1016/j.jhep.2021.04.026
|
[52]
|
Hegyi, P.J., Vancsa, S., Ocskay, K., et al. (2021) Metabolic Asso-ciated Fatty Liver Disease Is Associated with an Increased Risk of Severe COVID-19: A Systematic Review with Me-ta-Analysis. Frontiers in Medicine, 8, Article 626425.
https://doi.org/10.3389/fmed.2021.626425
|
[53]
|
Pan, L., Huang, P., Xie, X., et al. (2021) Metabolic Associated Fatty Liver Disease Increases the Severity of COVID-19: A Meta-Analysis. Digestive and Liver Disease, 53, 153-157. https://doi.org/10.1016/j.dld.2020.09.007
|
[54]
|
Singh, A., Hussain, S. and Antony, B. (2021) Non-Alcoholic Fatty Liver Disease and Clinical Outcomes in Patients with COVID-19: A Comprehensive Systematic Review and Me-ta-Analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15, 813-822. https://doi.org/10.1016/j.dsx.2021.03.019
|
[55]
|
Duengelhoef, P., Hartl, J., Ruther, D., et al. (2022) SARS-CoV-2 Vaccination Response in Patients with Autoimmune Hepatitis and Autoimmune Cholestatic Liver Disease. United Euro-pean Gastroenterology Journal, 10, 319-329.
https://doi.org/10.1002/ueg2.12218
|
[56]
|
Schneider, L., Schubert, L., Winkler, F., et al. (2022) SARS-CoV-2 Vac-cine Response in Patients with Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 20, 2145-2147. https://doi.org/10.1016/j.cgh.2022.04.006
|
[57]
|
Li, H., Wang, Y., Ao, L., et al. (2022) Association between Immu-nosuppressants and Poor Antibody Responses to SARS-CoV-2 Vaccines in Patients with Autoimmune Liver Diseases. Frontiers in Immunology, 13, Article 988004.
https://doi.org/10.3389/fimmu.2022.988004
|